Author: Poole, Stephen; Clark, Tristan W.
Title: Rapid syndromic molecular testing in pneumonia: The current landscape and future potential Cord-id: rbblg4pu Document date: 2019_12_3
ID: rbblg4pu
Snippet: Community acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and ventilator associated pneumonia (VAP) are all associated with significant mortality and cause huge expense to health care services around the world. Early, appropriate antimicrobial therapy is crucial for effective treatment. Syndromic diagnostic testing using novel, rapid multiplexed molecular platforms represents a new opportunity for rapidly targeted antimicrobial therapy to improve patient outcomes and facilitate antib
Document: Community acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and ventilator associated pneumonia (VAP) are all associated with significant mortality and cause huge expense to health care services around the world. Early, appropriate antimicrobial therapy is crucial for effective treatment. Syndromic diagnostic testing using novel, rapid multiplexed molecular platforms represents a new opportunity for rapidly targeted antimicrobial therapy to improve patient outcomes and facilitate antibiotic stewardship. In this article we review the currently available testing platforms and discuss the potential benefits and pitfalls of rapid testing in pneumonia.
Search related documents:
Co phrase search for related documents- accurate test and low prevalence: 1, 2, 3
- accurate test and low sensitivity: 1, 2, 3, 4, 5, 6
- accurate test and lung disease: 1, 2
- acquire infection and low prevalence: 1, 2
- acquire infection and lung disease: 1, 2, 3, 4
- action plan and additional cost: 1
- additional cost and low prevalence: 1
Co phrase search for related documents, hyperlinks ordered by date